Glenmark Pharma concludes Hypertension Awareness Month in India, in association with more than 1000 Healthcare Professionals
May 25, 2023
‐ Partnered with more than 210 hospitals and clinics in 143 cities across the country
‐ Conducted 214 Hypertension public awareness rallies and screening camps
‐ Have reached out to more than 10 Million adults through multiple channels including its digital platform: www.bpincontrol.in
Glenmark Pharmaceuticals Limited (Glenmark), an innovation‐driven, global pharmaceutical company marked May asthe Hypertension Awareness Month. Glenmark partnered with more than 1000 healthcare professionals (HCPs) from more than 210 hospitals and clinics in 143 cities across the country, and organized 214 public awareness rallies and screening camps to create mass awareness around Hypertension (High Blood Pressure).
The rallies consisted of informative sessions led by HCPs, who provided detailed insights on the signs, symptoms, and preventive measures related to Hypertension. Subsequently, blood pressure screening camps were set up to offer the general public an opportunity to assess their blood pressure levels. As a result of this initiative, Glenmark successfully reached out to 10 Million adults, effectively raising awareness about the disease.
While speaking about this program, Alok Malik, Executive Vice President & Head of India Formulations, Glenmark Pharmaceuticals Ltd., said, “We at Glenmark are firmly committed to creating awareness and making a meaningful impact in the fight against hypertension in India. With increasing prevalence, it is crucial that we prioritize raising awareness about this silent killer among the Indian population including young adults above the age of 18. Through our initiatives, we aim to empower individuals with knowledge about the risks and the importance of early detection, and management. Together, we can make a significant difference in improving the health outcomes of millions affected by this condition."
|
|
|
Glenmark has been at the forefront of raising awareness and promoting the diagnosis of hypertension among the Indian population. With its anti‐hypertension medication, Telma®, Glenmark has emerged as a leader in the hypertension category, demonstrating its commitment to addressing this health concern. The company had also launched the #TakeChargeAt18 campaign to drive Hypertension awareness and screening of Indian adults above 18 years of age. The company has already reached out to millions of Indian adults through multiple channels and campaigns including its digital platform: www.bpincontrol.in. In 2020, Glenmark launched the world’s first‐ever Hypertension awareness symbol – “The BP logo” in association with HSI (Hypertension society of India) and API (Association of Physicians of India).
Hypertension, a prevalent cardiovascular disease (CVD) risk factor, affects approximately 30% of adults in India1. Alarmingly, CVD is the leading cause of death in the country, responsible for almost one‐third of all mortality cases. India has established a goal of achieving a 25% relative reduction in the prevalence of high blood pressure (BP) among individuals aged 18 years and older by 2025, as part of its efforts to tackle this issue effectively2. Achieving this goal requires a concerted effort to enhance awareness around hypertension, as it serves as a crucial facilitator for encouraging people to proactively manage this condition. Additionally, greater awareness will emphasize the significance of adopting effective management strategies.
About Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is an innovation‐driven, global pharmaceutical company with a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 10 world‐class manufacturing facilities spread across 4 continents, and operations in over 80 countries. In Vivo/Scrip 100 positions Glenmark amongst the Top 100
Companies Ranked by R&D and Pharmaceutical Sales, 2021; while Generics Bulletin/In Vivo places it in the Top 50 Generics and Biosimilars Companies Ranked by Sales, 2021. Glenmark has impacted over 2.6 million lives over the last decade through its CSR interventions. For more information, visit www.glenmarkpharma.com. You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma).
Glenmark Pharmaceuticals
May 25, 2023
Need good help?
Check out our Services
Press Release Distribution & Writing Services
More News From Glenmark Pharmaceuticals
∙ Glenmark Pharma agrees to divest a 75% stake in its subsidiary Glenmark Life Sciences to Nirma Limited, at a price of INR 615/‐ per share implying an equity valuation of INR 75,354 mn. ∙ Glenmark Pharma ...
∙ The initiative aims to raise awareness and combat stigma associated with the skin pigmentation disorder (vitiligo). ∙ The special cover features the winning artwork from a painting competition of ...
∙ The collaboration to create awareness on the right age (18 years) to monitor blood pressure at home ∙ Aims to reach out to around 92,000 Healthcare Professionals (HCPs) and around Ten crore Indians in one ...
Similar News
∙ Glenmark Pharma agrees to divest a 75% stake in its subsidiary Glenmark Life Sciences to Nirma Limited, at a price of INR 615/‐ per share implying an equity valuation of INR 75,354 mn. ∙ Glenmark Pharma ...
vgaurd_3443.png&width=150 "V-Guard")